secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001104659-24-096647
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium closes $525M Ironshore acquisition; adds Jornay PM, boosts 2024 outlook
--------------------------------------------------------------------------------

- Ironshore acquired for $525M cash plus potential $25M milestone based on Jornay PM 2025 net revenue.
- Jornay PM (ADHD) expected >$100M net revenue in 2024; prescriptions grew 32% YoY in H1 2024.
- 2024 guidance updated: product revenue $620-635M, adjusted EBITDA $395-405M, reflecting four months of Ironshore.
- Financed with $200M cash and $325M draw on new $646M term loan; interest rate reduced 300 bps.
- Establishes presence in neurology/ADHD; Jornay PM poised as leading growth driver; patents to 2032.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924096647/0001104659-24-096647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924096647/tm2423139d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-096647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer